Free Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1208 - 1211
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2019250
Published online 06 January 2020

Anticorps (DCI*) Cible(s) Nom commercial Firmes
abciximab GPIIbIIIa/ Réopro Centocor / Janssen /
CD11b/CD18 Eli Lilly and Company
αvβ3
adalimumab TNF-α Humira Cambridge Antibody Technology(CAT) / AbbVie
adécatumumab EpCAM - Micromet / Merck
aducanumab amyloïde β - Neurimmune / Biogen
(A-β fibrillaire)
ado-trastuzumab emtansine (DM1) HER2/neu Kadcyla Genentech (Roche) / Lonza
aérubumab Ps°°°° Aerucin Aridis Pharmaceuticals
alemtuzumab CD52 Lemtrada Sanofi Genzyme
alirocumab PCSK9++ Praluent Sanofi-Aventis
anifrolumab IFNAR1 - Medimmune LLC / AstraZeneca
atézolizumab PD-L1 Tecentriq Genentech (Roche+)
avélumab PD-L1 Bavencio Merck Sharp & Dohme / Pfizer
basiliximab IL-2Rα (CD25) Simulect Novartis
bavituximab Phosphatidylsérine - Peregrine Pharmaceuticals
bélantamab mafodotine. BCMA (TNFRSF17) - GlaxoSmithKline
bélimumab BLyS (BAFF) Benlysta GlaxoSmithKline
benralizumab IL-5R Fasenra AstraZeneca
bévacizumab VEGF-A Avastin Roche
bézlotoxumab entérotoxine B Zinplava Merck Sharp & Dohme
Clostridium difficile
bimékizumab IL-17A/F - UCB
blésélumab CD40 - Kiowa Kirin Pharmaceuticals
blinatumomab CD3εxCD19 Blincyto Micromet / Amgen
bococizumab PCSK9 - Pfizer
brentuximab védotine CD30 Adcetris Seattle Genetics
burosumab FGF23 Crysvita Kyowa Hakko Kirin Pharma
cabiralizumab CSF1-R (CD115) - Five Prime Therapeutics/ Bristol-Myers Squibb
camrélizumab PD-1 - Jiangsu HengRui Medicine
canakinumab IL-1β Ilaris Novartis
caplacizumab vWF Cablivi Sanofi
catumaxomab CD3ε x EpCAM Removab Fresenius Biotech / Trion Pharma
cémiplimab PD-1 (CD279) Libtayo Regeneron / Sanofi
cergutuzumab amunaleukin ACE - Roche
certolizumab pégol TNF-α  Cimzia UCB Pharma
cétrélimab PD-1 (CD279) - Janssen
cétuximab EGF-R Erbitux Imclone / Merck Serono
conatumumab TRAIL-R2(DR5, APO-2) - Amgen / Takeda
concizumab TFPI°°° - Novo Nordisk
cosfroviximab Gp surface Ebola virus ZMapp Mapp Biopharmaceuticals
crénézumab amyloïde β(A-β fibrillaire) - Genentech (Roche)
cusatuzumab CD70 - Argenx / Janssen Cilag
dacétuzumab CD40 - Seattle Genetics / Genentech
daclizumab CD25 (IL-2Rα) Zinbryta Protein Design Labs BioPharma / Biogen / AbbVie
dapirolizumab pégol CD40L (CD154) - UCB Pharma
daratumumab CD38 Darzalex Janssen
dénosumab RANKL Prolia / Xgeva Amgen
dépatuxizumab madofotine EGF-RvIII - AbbVie
dinutuximab bêta GD2 Qarziba EUSA Pharma / Jazz Pharmaceuticals
diridavumab HA## - Janssen
drozitumab TRAIL-R2(DR5, APO-2) - Genentech (Roche)
dupilumab IL-4/IL-13Rα Dupixent Regeneron / Sanofi
durvalumab PD-L1 Imfinzi MedImmune LLC / AstraZeneca
éculizumab C5 Soliris Alexion Pharmaceuticals
éfalizumab CD11a Raptiva Genentech / Merck Serono
éfungumab Hsp90≠≠ Mycograb NeuTec Pharma / Novartis
élotuzumab SLAMF7 Empliciti Bristol-Myers Squibb
émactuzumab CSF1-R (CD115) - Genentech / Roche
émicizumab facteurs IXa x X Hemlibra Chugai (Roche)
enfortumab védotin nectine 4 - Seattle Genetics
énoblituzumab. B7-H3 (CD276) - MacroGenics
eptinézumab CGRP$$ - Alder Biopharmaceuticals
érénumab CGRP Aimovig Amgen / Novartis
erlizumab CD18 - Genentech (Roche)
ertumaxomab HER2/neu x CD3εx RFcγI/II/III - Fresenius Biotech
étanercept TNF-α Enbrel Pfizer
étigilimab TIGIT - Oncomed / Mereo BioPharma
énoblituzumab B7-H3 (CD276) - MacroGenics
évolocumab PCSK9++ Repatha Amgen
farlétuzumab Folate receptor 1 - Morphotek
felvizumab F§§(protéine de fusion) - GlaxoSmithKline
flotétuzumab CD123 x CD3e - MacroGenics
foravirumab gp I et gpIII§§§ - Crucell / Sanofi Pasteur
frémanézumab CGRP Ajovy Teva
frésolimumab TGF-β - Genzyme (Sanofi)
futuximab EGFR (Erb1, HER1) - Symphogen
galcanézumab CGRP Emgality Eli Lilly & Company
galiximab CD80 Biogen (ex-Biogen Idec)
ganténérumab amyloïde β(A-β fibrillaire) - Roche
gédivumab HA - Genentech (Roche)
gemtuzumab ozogamicin CD33 Mylotarg Celltech / Wyeth
golimumab TNF-α Simponi Janssen
grémubamab PcrV et PsI++++ - MedImmune (AstraZeneca)
guselkumab IL-23Rp19 Tremfya Janssen
ibalizumab CD4 Trogarzo Theratechnologies
ibritumomab tiuxetan CD20 Zevalin Spectrum Pharmaceuticals / Acrotech Biopharma
idarucizumab Dabigatran Praxbind Boehringer Ingelheim
inclacumab Sélectine P - Roche
infliximab TNF-α Remicade NYU°° / Janssen
inotuzumab ozogamicine CD22 Besponsa Pfizer
ipilimumab. CTLA-4 Yervoy Medarex / Bristol-Myers Squibb
isatuximab CD38 - Sanofi
iscalimab CD40 - Xoma / Novartis
ixékizumab IL-17A Taltz Eli Lilly & Company
lacnotuzumab CSF-R (CD115) - Novartis
lanadélumab kallicréine Takhzyro Takeda / Shire
larcaviximab Gp surface Ebola virus ZMapp Mapp Biopharmaceuticals
lenvervimab Ag HBs§ - GC Pharma
léronlimab CCR5 - CytoDyn
lexatumumab TRAIL-R2(DR5, APO-2) - Human Genome Sciences / Cambridge Antibody Technology
ligélizumab IgE - Novartis
lirilumab KIR2DL1/L2/L3- - Innate Pharma / Bristol-Myers Squibb
loncastuximab tésirine CD19 - ADC Therapeutics
lucatumumab CD40 - Chiron / Xoma / Novartis
lulizumab pégol CD28 - Bristol-Myers Squibb
lumiliximab CD23 (RFcεII) - Biogen Idec
mapatumumab TRAIL-R1 (DR4) - Human Genome Sciences (GlaxoSmith Kline)/ Cambridge Antibody Technology (AstraZeneca)
magrolimab CD47 - Forty Seven Inc.
mirvétuximab soravtansine FOLR1 - ImmunoGen
mitazalimab CD40 - Alligator Biosciences / Janssen
modotuximab HER1 (ErbB-1) - Symphogen
mogamulizumab CCR4 Poteligeo BioWa / Kyowa Hakko Kirin Pharma
monalizumab CD94/NKG2A - Innate Pharma / AstraZeneca
mosunétuzumab CD20 x CD3e - Genentech (Roche)
motavizumab F(protéine de fusion) Numax MedImmune (AstraZeneca)
moxétumomab pasudotox CD22 Lumoxiti AstraZeneca / Innate Pharma
muromonab CD3ε Orthoclone OKT3 Janssen-Cilag
naptumomab estéfénatox 5T4°°°°° - Active Biotech
natalizumab α4β1(VLA-4$) Tysabri Biogen / Élan
nécitumumab EGFR Portrazza Eli Lilly & Company
niversimab F(protéine de fusion) - MedImmune (AstraZeneca)Sanofi Pasteur
nivolumab PD-1 Opdivo Medarex / Bristol-Myers Squibb
obiltoxaximab PA# exotoxine(Anthrax) Anthim Elusys Therapeutics
obinutuzumab CD20 Gazyvaro / Gazyva Glycart Biotechnology (Roche)
ocrélizumab CD20 Ocrevus Roche
ofatumumab CD20 Arzerra Genmab / GlaxoSmithKline
omalizumab IgE Xolair Novartis
oportuzumab monatox EpCAM Vicinium Viventia Bio
otélixizumab CD3 - Tolerx / GlaxoSmithKline
otilimab GM-CSF - Morphosys / GlaxoSmithKline
oxélumab Ox40L (CD223) - Genentech (Roche)
pagibaximab Acide lipotéichoïque$$$ - Biosynexus
palivizumab VRS+++ Synagis MedImmune (AstraZeneca)
panitumumab EGFR
patéclizumab Lymphotoxine-α - Genentech (Roche)
pembrolizumab PD-1 Keytruda Merck Sharp and Dohme
pertuzumab HER2/neu Perjeta Genentech (Roche)
pexélizumab C5 - Alexion Pharmaceuticals
pidilizumab PD-1 (CD279) - Medivation
polatuzumab védotine-piqq CD79b Polivy Genentech (Roche)
porgaviximab Gp de surface ZMapp Mapp Biopharmaceutical / Public Health Agency of Canada
prézalizumab ICOS-L (CD275) - Amgen
ramucirumab VEGF-R2 (KDR) Cyramza Eli Lilly & Company
ranibizumab VEGF-A Lucentis Genentech (Roche) / Novartis
ravagalimab CD40 - AbbVie
ravulizumab C5 Ultomiris Alexion Pharmaceuticals
raxibacumab PA exotoxine(Anthrax) ABthrax Human Genome Sciences / GlaxoSmithKline
rélatlimab LAG-3 (CD223) - Bristol-Myers Squibb
risankizumab IL-23Rp19 - Boehringer Ingelheim / AbbVie
rituximab CD20 Rituxan/Mabthera Genentech (Roche)
rolédumab Rhésus D - LFB° Group
rontalizumab IFN-α - Genentech / Chugai Pharmaceuticals
rovalpituzumab tésirine DLL3### Rova-T Stemcentrx / Abbvie
rovélizumab CD18 - Icos Corp. (Eli Lilly & Company)
ruplizumab CD40L (CD154) Antova Biogen
sacituzumab govitécan Trop-2 - Immunomedics
sarilumab IL-6Rα (CD126) Kevzara Regeneron / Sanofi Aventis
sécukinumab IL-17A Cosentyx Novartis
sélicrélumab CD40 - Roche
sévirumab gH### - PDL BioPharma / Novartis
sibrotuzumab Fibroblastactivation protein (FAP) - Boehringer Ingelheim Pharma
sintilimab PD-1 (CD279) Tyvit Innovent Biologics / Eli Lilly and Co
spartalizumab PD-1 (CD279) - Novartis
suptavumab F(protéine de fusion) - Regeneron Pharmaceuticals
suvratoxumab Staphylococcus aureus alpha toxin - MedImmune (AstraZeneca)
tavolimab OX-40 (CD134) - MedImmune (AstraZeneca)
téfibazumab ClfA#### Aurexis Inhibitex (Bristol-Myers Squibb)
ténéliximab CD40 - ?
téplizumab CD3 - ProventionBio
théralizumab CD28 - TeGenero Immuno Therapeutics / TheraMAB
tigatuzumab TRAIL-R2(DR5, APO-2) - Daiichi Sankyo
tiragolumab TIGIT - Genentech (Roche)
tislélizumab PD-1 (CD279) - Beigene / Celgene (Bristol-Myers Squibb)
tocilizumab IL-6Rα (CD126) Actemra/RoActemra Chugai (Roche)
toralizumab CD40L (CD154) - Idec Pharmaceuticals
toripalimab PD-1 (CD279) - Shanghai Junshi Bioscience Co
tositumomab CD20 Bexxar GlaxoSmithKline
trastuzumab HER2/neu Herceptine Genentech / Roche
trastuzumab déruxtécan HER2/neu - Daiichi Sankyo
trastuzumab duocarmazine HER2/neu - Synthon Biopharmaceuticals BV
trémélimumab CTLA-4 (CD152) - Pfizer / Medimmune LLCAstraZeneca
ublituximab CD20 - LFB° Group / TG Therapeutics
urélumab 4-1BB (CD137) - Bristol-Myers Squibb
ustékinumab IL-23Rp40 Stelara Janssen
utomilumab 4-1BB (CD137) - Pfizer
vanalimab CD40 - Alligator BioScience /Janssen Biotech
varlilumab CD27 - Celldex therapeutics
védolizumab α4β7 Entyvio Takeda
veltuzumab CD20 - Immunomedics
volociximab α5β1 - PDL BioPharma / Biogen Idec
vopratélimab ICOS (CD278) - Jounce Therapeutics
*

DCI : dénomination commune internationale

+

F. Hoffmann-La Roche

++

Pro-protéine convertase subtilisine/kexine de type 9

+++

Virus respiratoire syncytial

++++

anticorps bispécifique anti-protéines sécrétrices de type III (PcrV) et anti-exopolysaccharide (PsI) de la paroi de Pseudomonas aeruginosa

°

Laboratoire Français du Fractionnement et des Biotechnologies

°°

New York University

°°°

Tissue factor pathway inhibitor

°°°°

Polysaccharide de surface de la paroi de Pseudomonas aeruginosa

°°°°°

Antigène oncofœtal

$

Very late antigen-4

$$

Calcitonin gene-related peptide

$$$

Acide lipotéichoïque de la paroi de Staphylococcus spp.

#

Antigène protecteur (protective antigen) de l’exotoxine de l’anthrax

##

Glycoprotéine HA de l’enveloppe du virus de la grippe A

###

Complexe glycoprotéique pentamérique gH de l’enveloppe du cytomégalovirus humain (HCMV)

####

Épitope de fixation à la fibrine du facteur d’agglutination A (ClfA) de la paroi de Staphylococcus aureus

§

Antigène de l’enveloppe du virus de l’hépatite B (VHB)

§§

Protéine de fusion F du virus respiratoire syncytial (VRS)

§§

Cocktail de deux AcM dirigés contre les sites antigéniques des glycoprotéines I (pour CR57) et III (pour CR4098) de l’enveloppe du virus de la rage (RV, rhabdovirus de la rage)

cocktail de trois AcM anti-glycoprotéine (Gp) de surface de l’enveloppe du virus Ebola (EBOV) : cosfroviximab, larcaviximab, porgaviximab

≠≠

Protéine chaperone Hsp90 de la paroi des levures Candida

###

Delta-like 3 protein

-

Killer inhibitory receptors


© 2019 médecine/sciences – Inserm

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.